Back to portfolio

AgeneBio, Inc.

Clinical stage CNS company developing therapeutics to address hippocampal overactivity

Based on the pioneering research of Ms. Michela Gallagher, PhD at Johns Hopkins University, AgeneBio was formed in 2008 to advance therapeutics against mild cognitive impairment due to Alzheimer’s disease, and MCI due to AD, the symptomatic, pre-dementia stage of Alzheimer’s. The company’s lead candidate – AGB-101 is in phase 3 trials. AgeneBio has also developed a novel GABAA α5 small molecule program in late discovery stage being investigated for the treatment of several diseases of the replica watches central nervous system including MCI due to AD, autism and schizophrenia.